FDA AdComm Schedule Boosts BioMarin, Sinks Sarepta
This article was originally published in Scrip
BioMarin Pharmaceutical Inc.'s investors pushed shares of the firm up 6% in morning trading on Oct. 14 after a notice was published early in the Federal Register – the place where the US government informs the public of federal actions, including plans for public meetings – confirming the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) is set to examine the company's new drug application (NDA) for its Duchenne muscular dystrophy medicine drisapersen Nov. 24.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.